autosomal recessive limb-girdle muscular dystrophy type 2I

disease
On this page

Also known as autosomal recessive limb-girdle muscular dystrophy caused by mutation in FKRPFKRP autosomal recessive limb-girdle muscular dystrophyLGMD-FKRP relatedLGMD2Ilimb-girdle muscular dystrophy due to FKRP deficiencylimb-girdle muscular dystrophy type 2IMDDGC5muscular dystrophy-dystroglycanopathy (Limb-girdle) type C, 5muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5muscular dystrophy-dystroglycanopathy (limb-girdle), type C5

Summary

autosomal recessive limb-girdle muscular dystrophy type 2I (MONDO:0011787) is a disease caused by FKRP (GenCC Definitive), with 2 cohort genes and 8 clinical trials. Top therapeutic interventions include ribitol.

At a glance

  • Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
  • Causal gene: FKRP (GenCC Definitive)
  • Cohort genes: 2
  • ClinVar variants: 326
  • Phenotypes (HPO): 17
  • Clinical trials: 8

Clinical features

Epidemiology

Prevalence records

3 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Point prevalence1-9 / 100 000EuropeValidated
Point prevalence1-9 / 1 000 0000.43United KingdomValidated
Point prevalence1-9 / 100 0001.85NorwayValidated

Signs & symptoms

Clinical features (HPO)

17 HPO clinical features (Orphanet curated; top 17 by frequency):

HPO IDTermFrequency
HP:0003236Elevated circulating creatine kinase concentrationVery frequent (80-99%)
HP:0003560Muscular dystrophyVery frequent (80-99%)
HP:0003701Proximal muscle weaknessVery frequent (80-99%)
HP:0030099Reduced muscle fiber alpha dystroglycanVery frequent (80-99%)
HP:0001290Generalized hypotoniaFrequent (30-79%)
HP:0002515Waddling gaitFrequent (30-79%)
HP:0003547Shoulder girdle muscle weaknessFrequent (30-79%)
HP:0003749Pelvic girdle muscle weaknessFrequent (30-79%)
HP:0005109Abnormality of the Achilles tendonFrequent (30-79%)
HP:0008981Calf muscle hypertrophyFrequent (30-79%)
HP:0001270Motor delayOccasional (5-29%)
HP:0001644Dilated cardiomyopathyOccasional (5-29%)
HP:0002359Frequent fallsOccasional (5-29%)
HP:0002650ScoliosisOccasional (5-29%)
HP:0003551Difficulty climbing stairsOccasional (5-29%)
HP:0009046Difficulty runningOccasional (5-29%)
HP:0030092Reduced muscle fiber merosinOccasional (5-29%)

Identifiers

Disease identifiers

FieldValue
Canonical nameautosomal recessive limb-girdle muscular dystrophy type 2I
Mondo IDMONDO:0011787
MeSHC564612
OMIM607155
Orphanet34515
DOIDDOID:0110299
NCITC126739
SNOMED CT718180000
UMLSC1846672
MedGen339580
GARD0012533
Is cancer (heuristic)no

Also known as: autosomal recessive limb-girdle muscular dystrophy caused by mutation in FKRP · FKRP autosomal recessive limb-girdle muscular dystrophy · LGMD-FKRP related · LGMD2I · limb-girdle muscular dystrophy due to FKRP deficiency · limb-girdle muscular dystrophy type 2I · MDDGC5 · muscular dystrophy-dystroglycanopathy (Limb-girdle) type C, 5 · muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5 · muscular dystrophy-dystroglycanopathy (limb-girdle), type C5

Data availability: 326 ClinVar variants · 4 GenCC gene-disease records · 4 cell lines.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal recessive diseaseautosomal recessive limb-girdle muscular dystrophyautosomal recessive limb-girdle muscular dystrophy type 2I

Related subtypes (31): epidermolysis bullosa simplex 5B, with muscular dystrophy, autosomal recessive limb-girdle muscular dystrophy type 2A, autosomal recessive limb-girdle muscular dystrophy type 2B, autosomal recessive limb-girdle muscular dystrophy type 2C, autosomal recessive limb-girdle muscular dystrophy type 2H, autosomal recessive limb-girdle muscular dystrophy type 2F, autosomal recessive limb-girdle muscular dystrophy type 2G, autosomal recessive limb-girdle muscular dystrophy type 2E, autosomal recessive limb-girdle muscular dystrophy type 2D, autosomal recessive limb-girdle muscular dystrophy type 2J, autosomal recessive limb-girdle muscular dystrophy type 2K, autosomal recessive limb-girdle muscular dystrophy type 2L, autosomal recessive limb-girdle muscular dystrophy type 2M, autosomal recessive limb-girdle muscular dystrophy type 2O, autosomal recessive limb-girdle muscular dystrophy type 2N, autosomal recessive limb-girdle muscular dystrophy type 2Q, autosomal recessive limb-girdle muscular dystrophy type 2P, autosomal recessive limb-girdle muscular dystrophy type 2T, autosomal recessive limb-girdle muscular dystrophy type R18, autosomal recessive limb-girdle muscular dystrophy type 2U, limb-girdle muscular dystrophy due to POMK deficiency, autosomal recessive limb-girdle muscular dystrophy type 2X, autosomal recessive limb-girdle muscular dystrophy type 2W, autosomal recessive limb-girdle muscular dystrophy type 2Y, autosomal recessive limb-girdle muscular dystrophy type 2R1, muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 8, muscular dystrophy, limb-girdle, autosomal recessive 23, muscular dystrophy, limb-girdle, autosomal recessive 26, muscular dystrophy, limb-girdle, autosomal recessive 27, muscular dystrophy, limb-girdle, autosomal recessive 28, muscular dystrophy, limb-girdle, autosomal recessive 29

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

326 retrieved; paginated sample, class counts are floors:

141 uncertain significance, 49 conflicting classifications of pathogenicity, 43 likely pathogenic, 40 pathogenic/likely pathogenic, 29 likely benign, 16 pathogenic, 5 benign/likely benign, 3 benign

ClinVarVariant (HGVS)GeneClassificationReview
1068020NM_024301.5(FKRP):c.229C>T (p.Gln77Ter)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
1071118NM_024301.5(FKRP):c.540_570dup (p.Cys191fs)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
1395158NM_024301.5(FKRP):c.1187dup (p.Ala397fs)FKRPPathogeniccriteria provided, multiple submitters, no conflicts
1452218NM_024301.5(FKRP):c.1253G>A (p.Trp418Ter)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
1903512NM_024301.5(FKRP):c.230_234del (p.Gln77fs)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
1920325NM_024301.5(FKRP):c.949del (p.Cys317fs)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
1929555NM_024301.5(FKRP):c.692G>A (p.Trp231Ter)FKRPPathogeniccriteria provided, multiple submitters, no conflicts
197347NM_024301.5(FKRP):c.947C>G (p.Pro316Arg)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
2675707NM_024301.5(FKRP):c.1020C>G (p.Tyr340Ter)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
2675708NM_024301.5(FKRP):c.1216C>T (p.Gln406Ter)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
2732525NM_024301.5(FKRP):c.265C>G (p.Pro89Ala)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
282247NM_024301.5(FKRP):c.545A>G (p.Tyr182Cys)FKRPPathogeniccriteria provided, multiple submitters, no conflicts
282866NM_024301.5(FKRP):c.162_165dup (p.Phe56fs)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
284644NM_024301.5(FKRP):c.313C>T (p.Gln105Ter)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
287717NM_024301.5(FKRP):c.675del (p.Thr226fs)FKRPPathogeniccriteria provided, multiple submitters, no conflicts
289096NM_024301.5(FKRP):c.1267del (p.Arg423fs)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
289473NM_024301.5(FKRP):c.970G>T (p.Glu324Ter)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
2913953NM_024301.5(FKRP):c.1208dup (p.Arg404fs)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
408721NM_024301.5(FKRP):c.1083C>A (p.Tyr361Ter)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4219NM_024301.5(FKRP):c.1154C>A (p.Ser385Ter)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4220NM_024301.5(FKRP):c.1343C>T (p.Pro448Leu)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4221NM_024301.5(FKRP):c.826C>A (p.Leu276Ile)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4222NM_024301.5(FKRP):c.387_390dup (p.Asp131delinsThrTer)FKRPPathogenicno assertion criteria provided
4223NM_024301.5(FKRP):c.1486T>A (p.Ter496Arg)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4224NM_024301.5(FKRP):c.946C>A (p.Pro316Thr)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4226NM_024301.5(FKRP):c.1364C>A (p.Ala455Asp)FKRPPathogeniccriteria provided, multiple submitters, no conflicts
4228NM_024301.5(FKRP):c.160C>T (p.Arg54Trp)FKRPPathogeniccriteria provided, multiple submitters, no conflicts
4232NM_024301.5(FKRP):c.899T>C (p.Val300Ala)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4233NM_024301.5(FKRP):c.919T>A (p.Tyr307Asn)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
4235NM_024301.5(FKRP):c.1387A>G (p.Asn463Asp)FKRPPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 15 · Orphanet: 6 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
FKRPDefinitiveAutosomal recessiveautosomal recessive limb-girdle muscular dystrophy type 2I15

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
FKRPOrphanet:34515FKRP-related limb-girdle muscular dystrophy R9
FKRPOrphanet:370959Congenital muscular dystrophy with cerebellar involvement
FKRPOrphanet:370968Congenital muscular dystrophy with intellectual disability
FKRPOrphanet:370980Congenital muscular dystrophy without intellectual disability
FKRPOrphanet:588Muscle-eye-brain disease
FKRPOrphanet:899Walker-Warburg syndrome

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence2

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
FKRPHGNC:17997ENSG00000181027Q9H9S5Ribitol 5-phosphate transferase FKRPgencc,clinvar
STRN4HGNC:15721ENSG00000090372Q9NRL3Striatin-4clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
FKRPRibitol 5-phosphate transferase FKRPCatalyzes the transfer of a ribitol 5-phosphate from CDP-L-ribitol to the ribitol 5-phosphate previously attached by FKTN/fukutin to the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phos…
STRN4Striatin-4Calmodulin-binding scaffolding protein which is the center of the striatin-interacting phosphatase and kinase (STRIPAK) complexes.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Scaffold/PPI18.6×0.225
Other/Unknown10.9×0.805

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
FKRPOther/UnknownnoLicD/FKTN/FKRP_NTP_transf, LicD_transferase, FKRP_N
STRN4Scaffold/PPInoWD40_rpt, Striatin_N, WD40/YVTN_repeat-like_dom_sf

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)2
unknown0

Top tissues across cohort

TissueCohort genes
cardiac muscle of right atrium1
hindlimb stylopod muscle1
left ventricle myocardium1
left testis1
right testis1
sural nerve1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
FKRP230ubiquitousmarkerleft ventricle myocardium, cardiac muscle of right atrium, hindlimb stylopod muscle
STRN4232ubiquitousmarkerleft testis, right testis, sural nerve

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
STRN41,549
FKRP1,436

Structural data

PDB: 1 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
FKRPQ9H9S58

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
STRN4Q9NRL368.59

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 1. Enrichment computed across 2 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Matriglycan biosynthesis on DAG11815.7×0.001FKRP

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
pentitol metabolic process18426.0×0.002FKRP
filtration diaphragm assembly18426.0×0.002FKRP
pentose metabolic process14213.0×0.003FKRP
creatine metabolic process12106.5×0.003FKRP
connective tissue development12106.5×0.003FKRP
oxygen metabolic process12106.5×0.003FKRP
maintenance of protein localization in endoplasmic reticulum11685.2×0.003FKRP
localization of cell11404.3×0.003FKRP
connective tissue replacement11203.7×0.004FKRP
diaphragm development1936.2×0.004FKRP
regulation of modification of postsynaptic structure1936.2×0.004STRN4
protein import1842.6×0.004FKRP
skeletal muscle fiber differentiation1842.6×0.004FKRP
response to alcohol1766.0×0.004FKRP
reelin-mediated signaling pathway1601.9×0.004FKRP
respiratory system process1468.1×0.005FKRP
protein O-linked glycosylation via mannose1468.1×0.005FKRP
glial cell differentiation1443.5×0.005FKRP
skeletal muscle tissue regeneration1443.5×0.005FKRP
negative regulation of hippo signaling1351.1×0.006STRN4
protein tetramerization1312.1×0.006FKRP
neuromuscular process1263.3×0.007FKRP
basement membrane organization1255.3×0.007FKRP
adult walking behavior1247.8×0.007FKRP
glycolytic process1191.5×0.008FKRP
heart morphogenesis1187.2×0.008FKRP
camera-type eye development1179.3×0.008FKRP
response to activity1162.0×0.008FKRP
response to glucocorticoid1162.0×0.008FKRP
bone mineralization1135.9×0.010FKRP

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2

Druggability breadth: 0 of 2 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
FKRP00
STRN400

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug2FKRP, STRN4

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
FKRP0
STRN40

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified4
PHASE1/PHASE22
PHASE31
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05775848PHASE3ACTIVE_NOT_RECRUITINGStudy to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
NCT04800874PHASE2ACTIVE_NOT_RECRUITINGStudy of BBP-418 in Patients With LGMD2I
NCT05230459PHASE1/PHASE2RECRUITINGA Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
NCT02841267PHASE1/PHASE2COMPLETEDA Trial of PF-06252616 in Ambulatory Participants With LGMD2I
NCT05989620Not specifiedRECRUITINGLong-Term Development of Muscular Dystrophy Outcome Assessments
NCT02165358Not specifiedCOMPLETEDMuscle MRI in Becker Muscular Dystrophy and in Limb-girdle Muscular Dystrophy Type 2I
NCT03842878Not specifiedCOMPLETEDNatural History Study of Patients With Limb-Girdle Muscular Dystrophy 2I
NCT04001595Not specifiedUNKNOWNGlobal FKRP Registry

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
RIBITOL22